Rheumatoid Arthritis & Interstitial Lung Disease Medication

Trial Objective

The purpose of this study is to find out if people with rheumatoid arthritis and interstitial lung disease (ILD) can benefit from taking Pirfenidone.

Rheumatoid Arthritis & Interstitial Lung Disease Medication

Our researchers also want to determine if the medication can be taken safely without many side effects. Pirfenidone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). This study will compare the results of taking Pirfenidone to those of a placebo, a medication that looks like Pirfenidone but does not contain the drug. Participants may receive Pirfenidone or a placebo.

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, call 303.270.2852 or complete the form below.

Who Can Participate

Adults who have been diagnosed with rheumatoid arthritis and interstitial lung disease (RA-ILD) for at least six months.


Estimated Time Commitment

10 visits & 1 phone call (22 hours over 56 weeks)

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

Genentech, Inc.

Age

18-85


Gender

Any Gender

Principal Investigators


Request More Information

*
*
*
*